An acardiac acephalic monster following in-utero anti-epileptic drug exposure.

B. Kutlay,S. Bayramoğlu,A. Kutlar,N. Yeşildağlar

DOI: https://doi.org/10.1016/0301-2115(95)02337-2

1996-04-01

Abstract:

What problem does this paper attempt to address?

Gastrointestinal Stromal Tumors of the Stomach and Esophagus

Lauren Theiss,Carlo M. Contreras

DOI: https://doi.org/10.1016/j.suc.2019.02.012

IF: 3.537

2019-06-01

Surgical Clinics of North America

Abstract:Gastrointestinal stromal tumors (GISTs) arise anywhere along the gastrointestinal tract, most commonly as a result of c-kit or PDGFRA proto-oncogene mutations. Surgical resection is an important component of treatment. However, molecular profiling of GISTs has provided many insights into adjuvant and neoadjuvant therapy options. Imatinib, the most frequently studied medical therapy, has been shown in numerous studies to provide benefit to patients in both the neoadjuvant and adjuvant setting. Interval imaging is an important component of the treatment of GISTs and national surveillance recommendations should be followed.

surgery
Precision Oncology in Gastrointestinal Stromal Tumors

Hiba Mechahougui,Montemurro Michael,Alex Friedlaender

DOI: https://doi.org/10.3390/curroncol30050351

2023-04-30

Abstract:GIST (gastrointestinal stromal tumors) represent 20% of sarcomatous tumors and 1-2% of primary gastrointestinal cancers. They have an excellent prognosis when localized and resectable, though their prognosis is poor in the metastatic setting, with limited options after the second line until recently. Four lines are now standard in KIT-mutated GIST and one in PDGFRA-mutated GIST. An exponential growth of new treatments is expected in this era of molecular diagnostic techniques and systematic sequencing. Currently, the main challenge remains the emergence of resistance linked to secondary mutations caused by selective pressure induced by TKIs. Repeating biopsies to tailor treatments might be a step in the right direction, and liquid biopsies at progression may offer a non-invasive alternative. New molecules with wider KIT inhibition are under investigation and could change the catalog and the sequence of existing treatments. Combination therapies may also be an approach to overcome current resistance mechanisms. Here, we review the current epidemiology and biology of GIST and discuss future management options, with an emphasis on genome-oriented therapies.
[Management of gastrointestinal stromal tumors]

Sarah Watson,Clément Bonnet

Abstract:MANAGEMENT OF GASTROINTESTINAL STROMAL TUMORS. Gastrointestinal stromal tumors (GIST) are the most frequent sarcoma subtype. More than 80% of GIST are characterized by activating mutations in KIT or PDGFRA genes, but rare molecular subtypes exist. Localized GIST can be cured by surgery. Adjuvant treatment with imatinib is the gold standard in high-risk GIST presenting mutations sensitive to this tyrosine kinase inhibitor. The development of tyrosine kinase inhibitors targeting KIT and PDGFRA has revolutionized the prognosis of metastatic GIST, by increasing the median overall survival: from less than 18 months to more than 70 months within 20 years. Similary to other histological subtypes, the diagnostic and therapeutic management of GIST must be referred to sarcoma reference centers.
Understanding Gastric GIST: From Pathophysiology to Personalized Treatment

Doru-Florian-Cornel Moga,Gabriela Vlădoiu,Anca-Maria Frățilă,Andreea-Alina Dan,Daniel Popa,Valentin Oprea

DOI: https://doi.org/10.3390/jcm13143997

2024-07-09

Abstract:Background: Gastric gastrointestinal stromal tumors (GISTs) represent a subset of gastrointestinal tumors predominantly found in the stomach. Despite their rarity, these tumors carry significant implications for patient health and management. GISTs are potentially malignant tumors with unpredictable progression. They originate from the interstitial cells of Cajal, which are positioned between the intramural neurons and the smooth muscle cells of the digestive tract. These tumors are characterized primarily by mutations in the c-Kit gene, as well as other mutations such as those in the platelet-derived growth factor receptor alpha (PDGFRA) gene. Methods: Our comprehensive search across five databases initially yielded 2976 articles. After eliminating 197 duplicates, we screened the titles and abstracts of 2779 articles, excluding 2692 for not meeting the inclusion criteria. During the full-text screening, 16 more articles were excluded. Ultimately, 71 papers met the inclusion criteria and were included in our analysis. Results: Due to differences in study designs, inclusion criteria for patients, and reported outcomes, a meta-analysis was not conducted. The accurate diagnosis of GIST is established through histopathological examination and immunohistochemistry. Histopathologically, GISTs are classified into three main types: spindle cell, epithelioid, and mixed. The therapeutic management of GIST involves surgery, endoscopic treatment, and chemotherapy. Conclusions: The prognosis for GIST patients depends on various factors, including risk category, disease stage, applied treatments, and recurrence post-treatment. A significant recent advancement comes from artificial intelligence, which can be increasingly involved in both the diagnosis and treatment of this tumor.
Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research

Lei Cao,Wencong Tian,Yongjie Zhao,Peng Song,Jia Zhao,Chuntao Wang,Yanhong Liu,Hong Fang,Xingqiang Liu

DOI: https://doi.org/10.1055/s-0044-1789204

2024-08-22

Abstract:Although gastrointestinal stromal tumors (GISTs) has been reported in patients of all ages, its diagnosis is more common in elders. The two most common types of mutation, receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor a (PDGFRA) mutations, hold about 75 and 15% of GISTs cases, respectively. Tumors without KIT or PDGFRA mutations are known as wild type (WT)-GISTs, which takes up for 15% of all cases. WT-GISTs have other genetic alterations, including mutations of the succinate dehydrogenase and serine-threonine protein kinase BRAF and neurofibromatosis type 1. Other GISTs without any of the above genetic mutations are named "quadruple WT" GISTs. More types of rare mutations are being reported. These mutations or gene fusions were initially thought to be mutually exclusive in primary GISTs, but recently it has been reported that some of these rare mutations coexist with KIT or PDGFRA mutations. The treatment and management differ according to molecular subtypes of GISTs. Especially for patients with late-stage tumors, developing a personalized chemotherapy regimen based on mutation status is of great help to improve patient survival and quality of life. At present, imatinib mesylate is an effective first-line drug for the treatment of unresectable or metastatic recurrent GISTs, but how to overcome drug resistance is still an important clinical problem. The effectiveness of other drugs is being further evaluated. The progress in the study of relevant mechanisms also provides the possibility to develop new targets or new drugs.
Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours

Yoichi Naito,Toshirou Nishida,Toshihiko Doi

DOI: https://doi.org/10.1007/s10120-023-01381-6

Gastric Cancer

Abstract:Gastrointestinal stromal tumours (GISTs) are soft-tissue sarcomas of the gastrointestinal tract. Surgery is the standard treatment for localised disease, but the risk of relapse and progression to more advanced disease is substantial. Following the discovery of the molecular mechanisms underlying GISTs, targeted therapies for advanced GIST were developed, with the first being the tyrosine kinase inhibitor (TKI) imatinib. Imatinib is recommended in international guidelines as first-line therapy to reduce the risk of GIST relapse in high-risk patients, and for locally advanced, inoperable and metastatic disease. Unfortunately, imatinib resistance frequently occurs and, therefore, second-line (sunitinib) and third-line (regorafenib) TKIs have been developed. Treatment options are limited for patients with GIST that has progressed despite these therapies. A number of other TKIs for advanced/metastatic GIST have been approved in some countries. Ripretinib is approved as fourth-line treatment of GIST and avapritinib is approved for GIST harbouring specific genetic mutations, while larotrectinib and entrectinib are approved for solid tumours (including GIST) with specific genetic mutations. In Japan, pimitespib, a heat shock protein 90 (HSP90) inhibitor, is now available as a fourth-line therapy for GIST. Clinical studies of pimitespib have indicated that it has good efficacy and tolerability, importantly not displaying the ocular toxicity of previously developed HSP90 inhibitors. Additional approaches for advanced GIST have been investigated, including alternative uses of currently available TKIs (such as combination therapy), novel TKIs, antibody-drug conjugates, and immunotherapies. Given the poor prognosis of advanced GIST, the development of new therapies remains an important goal.
New Developments in Gastrointestinal Stromal Tumor

ZHANG Wen,LI Jin

DOI: https://doi.org/10.3969/j.issn.1007-3639.2007.06.019

2007-01-01

Abstract:Gastrointestinal stromal tumor(GIST) is the most common mesenchymal malignancy of the GI tract. The mainstay of treatment is surgery. For patients in whom complete resection is not possible, or in patients with metastatic or recurrent disease, they are unresponsive to standard chemotherapy and to radiotherapy. There has been no effective systemic treatment for unresectable GIST or metastatic disease. Gain-of-function mutations of the KIT proto-oncogene occur in up to 90% of GIST, allowing constitutive activation of tyrosine kinase (i.e. auto-phosphorylation of tyrosine residues independent of ligand-receptor binding), leading to aberrant cell division and tumour growth. Imatinib selectively inhibits the tyrosine kinase activity associated with KIT, which forms the rationale for evaluating its effects in GIST. Herein, we review recent developments in treatment for GIST and implication for optimal treatment in these patients.
Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges

Wen-Kuan Huang,Chiao-En Wu,Shang-Yu Wang,Ching-Fu Chang,Wen-Chi Chou,Jen-Shi Chen,Chun-Nan Yeh

DOI: https://doi.org/10.1007/s11864-022-00996-8

2022-08-18

Current Treatment Options in Oncology

Abstract:Gastrointestinal stromal tumor (GIST), though rare, is the most common mesenchymal tumors of the gastrointestinal tract. KIT or PDGFRα mutation plays as an oncogenic driver in the majority of GISTs. Surgical resection is the only curative treatment for localized disease. The discovery of imatinib with promising anti-tumor effect and successive tyrosine kinase inhibitors (TKI), including second-line sunitinib and third-line regorafenib, revolutionized the management of advanced and metastatic GIST over the past two decades. Recently, ripretinib and avapritinib were approved for the fourth line setting and for PDGFRA exon 18-mutant GIST in first-line setting, respectively. Despite multi-line TKIs exerted ability of disease control, drug resistance remained an obstacle for preventing rapid disease progression. Experimental TKIs or novel therapeutic targets may further improve treatment efficacy. Immune checkpoint inhibitors such as anti-programmed cell death protein-1 (PD1) and anti-CTL-associated antigen 4 (CTLA-4) showed moderate response in early phase trials composed of heavily pretreated patients. KIT/PDGFRα wild-type GISTs are generally less sensitive to imatinib and late-line TKIs. Recent studies demonstrated that targeting fibroblast growth factor receptor signaling may be a potential target for the wild-type GISTs.

oncology
Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View

Chiao-En Wu,Chin-Yuan Tzen,Shang-Yu Wang,Chun-Nan Yeh

DOI: https://doi.org/10.3390/cancers11050679

2019-05-16

Cancers

Abstract:Gastrointestinal stromal tumors (GISTs) originating from the interstitial cells of Cajal are mesenchymal tumors of the gastrointestinal tract and have been found to harbor c-KIT mutations and KIT (CD117) expression since 1998. Later, PDGFRA mutations, SDH alterations, and other drive mutations were identified in GISTs. In addition, more and more protein markers such as DOG1, PKCθ were found to be expressed in GISTs which might help clinicians diagnose CD117-negative GISTs. Therefore, we plan to comprehensively review the molecular markers and genetics of GISTs and provide clinicians useful information in diagnostic and therapeutic strategies of GISTs. Twenty years after the discovery of KIT in GISTs, the diagnosis of GISTs became much more accurate by using immunohistochemical (IHC) panel (CD117/DOG1) and molecular analysis (KIT/PDGFRA), both of which constitute the gold standard of diagnosis in GISTs. The accurately molecular diagnosis of GISTs guides clinicians to precision medicine and provides optimal treatment for the patients with GISTs. Successful treatment in GISTs prolongs the survival of GIST patients and causes GISTs to become a chronic disease. In the future, the development of effective treatment for GISTs resistant to imatinib/sunitinib/regorafenib and KIT/PDGFRA-WT GISTs will be the challenge for GISTs.

oncology
Gastrointestinal Stromal Tumors and Other Mesenchymal Lesions of the Gut

Joel K. Greenson

DOI: https://doi.org/10.1097/01.mp.0000062860.60390.c7

IF: 8.209

2003-04-01

Modern Pathology

Abstract:In the past 5 years, there has been a paradigm shift in our understanding of gastrointestinal stromal tumors (GISTs). Once thought to be smooth muscle tumors, these uncommon neoplasms are now thought to differentiate along the lines of interstitial cells of Cajal, the pacemaker cells of the gut. Along with this understanding comes an exciting new drug therapy (Gleevec) that for the first time offers real hope to patients with malignant stromal tumors. Overall, approximately 60-70% of stromal tumors are from the stomach, 20-30% are from the small intestine, and <10% come from the esophagus, colon, rectum, omentum, and mesentery. Between 10 and 30% of GISTs are malignant. Stromal tumors should be studied in a site-specific fashion, as tumors from a given location in the gut have unique growth patterns and corresponding behaviors. Although the most important tool needed to diagnose a GIST is still a hematoxylin and eosin-stained section, a confirmatory CD117 stain is recommended (and may be required for drug therapy). True smooth muscle tumors, inflammatory fibroid polyps, fibromatoses, schwannomas, inflammatory myofibroblastic tumors, and solitary fibrous tumors all enter into the differential diagnosis of GISTs. This article reviews the histologic features of these tumors in the context of recent molecular genetic and immunohistochemical advances.

pathology
[Treatment Progress of Gastrointestinal Stromal Tumor].

Xin Ji,Jia-fu Ji

DOI: https://doi.org/10.3760/cma.j.issn.1671-0274.2013.03.026

2013-01-01

Abstract:Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Its pathogenesis is defined by mutations within the KIT and PDGFRα gene. Surgical resection is the only radical treatment at present, but recurrence is common. In recent years, targeted therapy with imatinib mesylate, which inhibits KIT kinase activity, represents the other cornerstone for the treatment of GIST. For resectable GIST, operation combined with neoadjuvant and adjuvant therapy with imatinib mesylate or other tyrosine kinase inhibitors can improve the prognosis of high-risk patients before or after complete resection. For unresectable GIST, targeted therapy with imatinib mesylate can effectively inhibit and ameliorate the progression of GIST.
Molecular Classification and Targeted Therapy of Gastrointestinal Stromal Tumors

WENG Zheng-hui,SUN Xi-tai

DOI: https://doi.org/10.13241/j.cnki.pmb.2011.12.054

2011-01-01

Abstract:The gastrointestinal stromal tumor(GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract,and was different from leiomyoma,neurogenic tumor,which occurs mainly with the Kit gene and platelet-derived growth factor receptor alpha gene mutation.Targeting KIT has led to a new treatment paradigm in GISTs.Imatinib and sunitinib,both tyrosine kinase inhibitors directed to KIT,were approved for first-and second-line treatment of metastatic and unresectable GISTs.In this article,we will review the molecular classification and targeted drug therapy of GISTs.
Molecular targeted therapy for the treatment of gastrointestinal stromal tumor

Jian LI

DOI: https://doi.org/10.3760/cma.j.issn.1673-9752.2013.04.004

2013-01-01

Abstract:Molecular targeted agents changed the therapeutic pattern on gastrointestinal stromal tumor (GIST).Imatinib of 400 mg/d is recommended to be the first line therapy for metastatic GIST.Escalation of imatinib dose or sunitinib could improve the overall survival of patients when the treatment with standard dose of imatinib failed.In addition,new targeted agents showed potential anti-tumor efficacy.Imatinib adjuvant therapy could improve the recurrence-free survival of GIST patients with median or high risk after complete tumor resection.Preoperative treatment with imatinib raises tumor resection rate,but whether it could provide survival benefit has not been proved.C-kit/PDGFRα gene mutation can predict the efficacy of imatinib and sunitinib,and it is helpful to screen out the GIST patients to receive imatinib adjuvant therapy.
Some Hot Spots in the Treatment of Gastrointestinal Stromal Tumor

SHI Ying-qiang,WANG Chun-meng

DOI: https://doi.org/10.3760/cma.j.issn.1006-9801.2010.02.002

2010-01-01

Abstract:Gastrointestinal stromal tumor (GIST) may be defined as mesenchymal tumors of the gastrointestinal tract,and the application of the tyrosine kinase inhibitor imatinib mesylate has changed the treatment style of the tumor.The surgical treatment is the only choice for the GIST patients before imatinib era,but now the individualized treatment combined with target therapy,surgery and laparoscope surery becomes the mainstay.The paper focus on the new development of preoperative biopsy,laparoscope surery,imatinib neoadjuvant and imatinib therapeutic effect evaluation in recent years.
A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric mass

Stefan Habringer,Jana Ihlow,Karsten Kleo,Anna Klostermann,Max Schmidt,Lidan Chai,Maren Knödler,Serge Leyvraz,Christian Sigler,Bruno Sinn,Georg Maschmeyer,Yvette Jegodka,Manuela Benary,Claus-Eric Ott,Ingeborg Tinhofer,Reinhold Schäfer,Markus Möbs,Ulrich Keller,Ulrich Keilholz,Damian T Rieke

DOI: https://doi.org/10.1093/oncolo/oyae137

2024-10-03

Abstract:A patient with gastrointestinal stroma tumor (GIST) and KIT p.V559D and BRAF p.G469A alterations was referred to our institutional molecular tumor board (MTB) to discuss therapeutic implications. The patient had been diagnosed with B-cell chronic lymphocytic leukemia (CLL) years prior to the MTB presentation. GIST had been diagnosed 1 month earlier. After structured clinical annotation of the molecular alterations and interdisciplinary discussion, we considered BRAF/KIT co-mutation unlikely in a treatment-naïve GIST. Discordant variant allele frequencies furthermore suggested a second malignancy. NGS of a CLL sample revealed the identical class 2 BRAF alteration, thus supporting admixture of CLL cells in the paragastric mass, leading to the detection of 2 alterations. Following the MTB recommendation, the patient received imatinib and had a radiographic response. Structured annotation and interdisciplinary discussion in specialized tumor boards facilitate the clinical management of complex molecular findings. Coexisting malignancies and clonal hematopoiesis warrant consideration in case of complex and uncommon molecular findings.
The management of metastatic GIST: current standard and investigational therapeutics

Ciara M. Kelly,Laura Gutierrez Sainz,Ping Chi

DOI: https://doi.org/10.1186/s13045-020-01026-6

2021-01-05

Abstract:Abstract Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. The majority of GISTs harbor gain of function mutations in either KIT or PDGFRα. Determination of the GIST molecular subtype upon diagnosis is important because this information informs therapeutic decisions in both the adjuvant and metastatic setting. The management of GIST was revolutionized by the introduction of imatinib, a KIT inhibitor, which has become the standard first line treatment for metastatic GIST. However, despite a clinical benefit rate of 80%, the majority of patients with GIST experience disease progression after 2–3 years of imatinib therapy. Second and third line options include sunitinib and regorafenib, respectively, and yield low response rates and limited clinical benefit. There have been recent FDA approvals for GIST including ripretinib in the fourth-line setting and avapritinib for PDGFRA exon 18-mutant GIST. This article aims to review the optimal treatment approach for the management of patients with advanced GIST. It examines the standard treatment options available but also explores the novel treatment approaches in the setting of imatinib refractory GIST.

oncology,hematology
Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies

Yang Yu,Mengdie Yu,Lijie Luo,Zijing Zhang,Haiping Zeng,Yan Chen,Zeyu Lin,Mengnan Chen,Wei Wang

DOI: https://doi.org/10.3389/fonc.2024.1405727

IF: 4.7

2024-07-13

Frontiers in Oncology

Abstract:Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours, arising mainly from the interstitial cells of Cajal (ICCs) of the gastrointestinal tract. As radiotherapy and chemotherapy are generally ineffective for GISTs, the current primary treatment is surgical resection. However, surgical resection is not choice for most patients. Therefore, new therapeutic strategies are urgently needed. Targeted therapy, represented by tyrosine kinase inhibitors (TKIs), and immunotherapy, represented by immune checkpoint inhibitor therapies and chimeric antigen receptor T-cell immunotherapy (CAR-T), offer new therapeutic options in GISTs and have shown promising treatment responses. In this review, we summarize the molecular classification and immune microenvironment of GISTs and discuss the corresponding targeted therapy and immunotherapy options. This updated knowledge may provide more options for future therapeutic strategies and applications in GISTs.

oncology
The Diagnosis and Treatment of Colorectal Gastrointestinal Stromal Tumors

徐烨,程晓斌,林建江,徐加鹤,王金海,刘凡隆,徐向明,陈文斌

DOI: https://doi.org/10.3760/cma.j.issn.1007-631x.2013.01.004

2013-01-01

Abstract:Objective To assess the clinicopathological features,treatment and prognosis of colorectal gastrointestinal stromal tumors (GISTs).Methods Clinical data of 49 patients diagnosed as colorectal GISTs between December 2000 and September 2009 were reviewed.The major clinicopathological features,treatment modalities and outcomes were retrospectively analyzed.Analysis of variarance (ANOVA)was applied to measurement data,while x2 or Fisher's exact test was assigned to enumeration data.The survival analysis was applied to estimate the prognosis of 49 patients undergoing operative treatment.Results The median age of the patients was 54 years old.There was no significant sexual deference in the incidence (49％ vs.51％).The onset of colorectal GISTs was insidious and the clinical symptoms were nonspecific.Main complain involved changes of defecation habit and fecal property,abdominal discomfort and bloody stool.Pathological signs of colorectal GISTs under microscope are spindle cells in beam form or knitting shape,and immunohistochemical characteristics shows the highly positive expression rates of CD117 and CD34.The recurrence rate in high risk patients after complete tumor resection is significantly higher than that in low risk (P =0.018),and the tumor-free survival time is also respectively shorter (P =0.011).Conclusions Clinical symptoms don't contribute much to the diagnosis of colorectal GISTs,while immunohistochemical staining is reliable in the identification of colorectal GISTs.Patients classified into very low and low risk groups can be cured with local excisions,while those in moderate or high risk group are recommended for radical excisions.The combination of complete resection and imatinib is recommended for a better prognosis.
An update on molecular genetics and drug resistance of gastrointestinal stromal tumors

HU Yu-yao,JI Feng

2008-01-01

International Journal of Digestive Diseases

Abstract:Most of gastrointestinal stromal tumors(GIST)show activating mutations of the genes coding for KIT or platelet-derived growth factor receptor α(PDGFRα).The growth of GIST could be repressed by the receptor tyrosine kinases(RTK) inhibitor imatinib(Gleevec).Several factors such as location,size,mitotic index and changes of molecular genetics can affect the level of response to imatinib,thus GIST should be evaluated according to pathological criteria and molecular context.
[Molecular Mechanism of Gastrointestinal Stromal Tumors and Progress in Drug Research].

Nikolaus Seiler,Benoit Duranton,Francis Raul,Zhi Hong,Craig E. Cameron,Jie Hong Hu,Charles Krieger,James O. Schenk,Laszlo Prokai,David F. Horrobin,Suprabhat Ray,Reema Rastogi,Atul Kumar

DOI: https://doi.org/10.3760/cma.j.issn.1671-0274.2016.11.025

2016-01-01

Abstract:The functional mutation of c-kit and platelet-derived growth factor receptor α (PDGFRA) which encode proto-oncogene receptor tyrosine kinase are the crucial pathogeneses of gastrointestinal stromal tumors(GISTs). 80%-85% c-kit gene mutation including exon 11,exon 9,exon 13,exon 17 and 5%-10% PDGFRA gene mutation such as exon 18, exon 12 are examined in GISTs. Neither of c-kit or PDGFRA gene mutation are called wide type GISTs. The pathogeneses of wild type GISTs are not clear. The deficiency of succinate dehydrogenase B(SDHB)-related insulin-like growth factor 1(IGF-1R) activation, BRAF gene mutation and neurofibromatosis type 1 may be related to progression of wild type GISTs. More than half of metastatic GISTs patients receiving imatinib treatment can develop to c-kit secondary mutations, which are responsible for secondary resistance. However, the reasons of imatinib resistance in GISTs without c-kit secondary mutation need to be explored. At present, many clinical trials are ongoing to evaluate new drugs in GISTs treatment, including nilotinib, masitinib, pazopanib, dovitinib, ponatinib, dasatinib, crenolanib, linsitinib and immunotherapy, which may bring resistance GISTs treatment to new hope. Next generation sequencing (NGS) and liquid biopsy will be very important in GISTs research and clinical practice.

An acardiac acephalic monster following in-utero anti-epileptic drug exposure.

Gastrointestinal Stromal Tumors of the Stomach and Esophagus

Precision Oncology in Gastrointestinal Stromal Tumors

[Management of gastrointestinal stromal tumors]

Understanding Gastric GIST: From Pathophysiology to Personalized Treatment

Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours

New Developments in Gastrointestinal Stromal Tumor

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges

Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View

Gastrointestinal Stromal Tumors and Other Mesenchymal Lesions of the Gut

[Treatment Progress of Gastrointestinal Stromal Tumor].

Molecular Classification and Targeted Therapy of Gastrointestinal Stromal Tumors

Molecular targeted therapy for the treatment of gastrointestinal stromal tumor

Some Hot Spots in the Treatment of Gastrointestinal Stromal Tumor

A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric mass

The management of metastatic GIST: current standard and investigational therapeutics

Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies

The Diagnosis and Treatment of Colorectal Gastrointestinal Stromal Tumors

An update on molecular genetics and drug resistance of gastrointestinal stromal tumors

[Molecular Mechanism of Gastrointestinal Stromal Tumors and Progress in Drug Research].